Concepedia

Author

Yan Moore

Ipsen (United Kingdom)ORCID

Also Known As

Y Moore, Y. Moore, YAN MOORE, Yan Moore

40

Publications

499

Citations

9

H-Index

21

Concepts

All Affiliations

Ipsen (United Kingdom)Ipsen (United States)Vall d'Hebron Hospital Universitari
YM

About

Yan Moore is an author at Ipsen (United Kingdom) specializing in oncology, cancer therapeutics, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

54

2

Pharmacology

3

3

39

3

Pathology

2

2

28

4

Health Sciences

1

1

11

5

Surgical Oncology

1

1

15

Yan Moore

×

8

Publications

383

Citations

8

H-Index

YearCitations

Treatment of Organ Confined Prostate Cancer with Third Generation Cryosurgery: Preliminary Multicenter Experience

Ken‐ryu Han, Jeff Cohen, Ralph Miller,

The Journal of Urology

2003

204

PILOT EXPERIENCE WITH REAL-TIME ULTRASOUND GUIDED PERCUTANEOUS RENAL MASS CRYOABLATION

Matthew J. Bassignani, Yan Moore, Laurence R. Watson,

The Journal of Urology

2004

64

Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase

Jasgit C. Sachdev, Pamela N. Münster, Donald W. Northfelt,

Breast Cancer Research and Treatment

2020

44

First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors.

Timothy A. Yap, Ecaterina E. Dumbrava, Jordi Rodón,

Journal of Clinical Oncology

2021

18

RESILIENT part 1: a phase 2 dose‐exploration and dose‐expansion study of second‐line liposomal irinotecan in adults with small cell lung cancer

Luis Paz‐Ares, David R. Spigel, Yuanbin Chen,

Cancer

2022

17

Phase II trial of BC-819 intravesical gene therapy in combination with BCG in patients with non-muscle invasive bladder cancer (NMIBC).

Sarel Halachmi, Ilan Leibovitch, Amnon Zisman,

Journal of Clinical Oncology

2018

15

Abstract P3-14-24: Overall Survival Benefit Observed with Lapatinib (L) Plus Paclitaxel (P) as First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer (MBC)

Z-Z Guan, BH Xu, Wichit Arpornwirat,

Cancer Research

2010

11

NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.

Zev A. Wainberg, Tanios Bekaii‐Saab, Richard Hubner,

Journal of Clinical Oncology

2020

10

Page 1